Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced on September 7, 2026 that...
Company
Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform
Hualan Biological Engineering Inc. (SHE: 002007) announced on September 8, 2026 that its novel influenza...
Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent
Suzhou AsiFlyer Biotechnology Co., Ltd. announced that on August 1, 2026 it signed a technology...
Sun-Novo Pharmaceutical and DeepMed Technology Sign Strategic Pact on AI‑Driven Drug R&D – Building Closed‑Loop “AI Design + Wet‑Lab Validation” Discovery System
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) and DeepMed Technology (Suzhou) Co., Ltd. have...
Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate
Liaocheng University and Shanghai Maiboxing Biotechnology Co., Ltd. have signed a cooperation agreement totaling RMB...
Clinical‑Stage Biopharma Revelyx Bio Launches with Exclusive Global License for YY003 – Ready‑to‑Use Recombinant Botulinum Toxin Type A
Clinical‑stage biopharmaceutical company Revelyx Bio, Inc. announced on August 31, 2026 its official launch, backed...
Eton Pharmaceuticals Licenses Auson’s Timolol Gel ASN001 for North America – Potential First Topical Therapy for Infantile Hemangioma in the U.S.
Auson Pharma (US), a wholly‑owned subsidiary of Shanghai Auson Pharmaceuticals, announced on August 6, 2026...
China Medical System Licenses Leios Therapeutics’ Injectable Fat‑Reduction Therapy 10XB‑101 in Greater China, Alongside Strategic Equity Investment
Leios Therapeutics, an innovative aesthetic therapies company, announced on August 31, 2026 that it has...
China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation
Panboron (Hainan) BNCT Hospital, a subsidiary of China Biotech Services Holdings Limited (HKG: 8037), officially...
Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018
Guangdong Taienkang Pharmaceutical Co., Ltd. (SHE: 301263) announced on September 8, 2026 the completion of...
HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems
HepaBio Therapeutics announced that it has raised tens of millions of RMB in Series A...
NMPA Accepts MediLink Therapeutics’ NDA for Tam‑Peli, Self‑Developed B7‑H3‑Targeting ADC for Relapsed Small Cell Lung Cancer
MediLink Therapeutics announced that the New Drug Application (NDA) for Tam‑Peli (tamatanmab pelidotin for injection;...
Insilico Medicine and MobiDrop Sign Strategic Partnership to Advance AI‑Ready Single‑Cell Data for Drug Discovery
Insilico Medicine (HKG: 3696) signed a strategic cooperation agreement with MobiDrop, under which the two...
Innovent Biologics’ Suzhou Base Passes EMA On‑Site Inspection, Securing EU GMP Certification on First Attempt
Innovent Biologics (HKG: 1801) announced that its Suzhou commercialization base successfully passed the on‑site Good...
Santen’s Atropine Eye Drops RYJUSEA Wins NDA Acceptance From China’s NMPA for Myopia Progression
Santen Pharmaceutical (TYO: 4536) announced that the New Drug Application (NDA) for its atropine sulfate...
Anglikang Pharmaceuticals Terminates Affinity Partnership for IMD‑1005, Novel Tumor Microenvironment‑Activated CD47 Antibody
Anglikang Pharmaceuticals (SHE: 002940) announced that its partnership with Affinity for the IMD‑1005 project will...
Jenscare’s LuX‑Valve Plus Wins Hong Kong Approval, Expanding Global Footprint of Transcatheter Tricuspid Valve Replacement System
Ningbo Jenscare Scientific Co., Ltd. (HKG: 9877) announced that its transcatheter tricuspid valve replacement system,...
TenNor Therapeutics Reports Positive Phase IIa Top‑Line Results for TNP‑2092 in Prosthetic Joint Infection; First‑in‑Class Triple‑Target Candidate Advances to Phase IIb
TenNor Therapeutics (HKG: 6872) today announced positive top‑line results from its Phase IIa proof‑of‑concept clinical...
MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China
Merck & Co., Inc. (MSD; NYSE: MRK) announced that its PD-1 inhibitor KEYTRUDA (pembrolizumab) has...
Trinomab’s Retavibart Wins NMPA Priority Approval as RSV Prevention Monoclonal Antibody Xinduotuo
Zhuhai Trinomab Pharmaceutical Co., Ltd. (SHA: 688806) announced that its Category 1 pediatric innovative drug,...